Urology News and Research

Latest Urology News and Research

Taiho Pharmaceutical announces early stage data for eight novel oncology compounds

Taiho Pharmaceutical Co., Ltd., the developer of the first orally available fluorouracil (FU) Chemotherapeutic treatment (TS-1/S-1), is presenting early stage data for eight novel oncology compounds, including potential first-in-class therapies.

7 Nov 2012

Monoclonal antibody boosts cholesterol reduction

Adding a monoclonal antibody that blocks the breakdown of lipid receptors to atorvastatin therapy further reduces low-density lipoprotein cholesterol levels in patients with primary hypercholesterolemia, show study findings.

6 Nov 2012

Endo, Bioniche decide to end second Urocidin Phase III trial on non-muscle-invasive bladder cancer

Bioniche Life Sciences Inc., a research-based, technology-driven Canadian biopharmaceutical company, today announced that a second Phase III clinical trial with Urocidin in non-muscle-invasive bladder cancer is being discontinued.

5 Nov 2012

Men with prostate cancer can benefit from active surveillance

With active surveillance many men with prostate cancer could dispense with radiation treatment and surgery, and thus avoid adverse effects such as incontinence and impotence. This is the outcome of a study of almost 1,000 men diagnosed with prostate cancer conducted at Sahlgrenska Academy, University of Gothenburg, Sweden.

3 Nov 2012

Toilet training method not related to urinary accidents in children

Parents: stop worrying about which toilet training method to use - where urinary accidents in children are concerned, it doesn't matter. This clearly-stated message, published today in Clinical Pediatrics by physician researchers from the University of Medicine and Dentistry of New Jersey (UMDNJ)-Robert Wood Johnson Medical School and The Bristol-Myers Squibb Children's Hospital at Robert Wood Johnson University Hospital, emphasizes that the method of training chosen by parents is not the cause of urinary accidents in children.

3 Nov 2012

Imatinib mesylate effectively treats children with neurofibromatosis type 1 tumors

Physician-researchers at Indiana University School of Medicine have reported the first effective therapy for a class of previously untreatable and potentially life-threatening tumors often found in children.

2 Nov 2012

Multiple sclerosis disease activity reduced by leukaemia drug, even when first-line treatment has failed

A drug which was originally developed to treat leukaemia and other cancers of the immune system offers substantial improvements over existing treatments in reducing relapse rates for people with multiple sclerosis (MS), even when they have not responded well to first-line treatment, according to the results of two phase 3 trials published Online First in The Lancet.

1 Nov 2012

Encouraging results from stereotactic radiosurgery Phase I trial on kidney cancer

A first-of-its-kind clinical trial conducted at University Hospitals (UH) Case Medical Center Seidman Cancer Center has shown encouraging results for the use of stereotactic radiosurgery to treat kidney cancer.

1 Nov 2012

Watson acquires Actavis

Watson Pharmaceuticals, Inc. today announced that it has completed the acquisition of the Actavis Group for EUR 4.25 billion.

1 Nov 2012

Prognostic impact of Gleason score modernization undetermined

A review of contemporary grading systems for prostate cancer has found that modernization of the Gleason grading system results in more accurate grading for radical prostatectomy than older systems.

31 Oct 2012

High vitamin D levels associated with protection against bladder cancer

High levels of vitamin D are associated with protection against bladder cancer, according to a multidisciplinary study coordinated by molecular biologists and epidemiologists from the Spanish National Cancer Research Centre (CNIO), the conclusions of which are being published today in the Journal of National Cancer Institute (JNCI) .

31 Oct 2012

Sequana Medical announces CE mark approval of alfapump for patients with malignant ascites

Sequana Medical is pleased to announce that it has received CE mark approval for use of its alfapump system in patients with ascites caused by cancer (malignant ascites).

30 Oct 2012

Metabolic syndrome increases erectile dysfunction risk

The metabolic syndrome is an independent risk factor for the development of erectile dysfunction in Chinese men, especially among those who are middle-aged, show study findings.

29 Oct 2012

Scientists identify mechanism via Top2b enzyme that drives doxorubicin-induced heart damage

Doxorubicin, a 50-year-old chemotherapy drug still in widespread use against a variety of cancers, has long been known to destroy heart tissue, as well as tumors, in some patients.

29 Oct 2012

FDA approves Watson’s generic Actos

Watson Pharmaceuticals, Inc. today announced that Watson has launched a generic version of Actos (Pioglitazone Hydrochloride 15mg, 30mg and 45mg tablets) after receiving final approval today from the U.S. Food and Drug Administration (FDA).

29 Oct 2012

NAFC conducts online survey to examine women’s perceptions about overactive bladder

The National Association For Continence (NAFC) is conducting an anonymous online survey to understand the perceptions women, age 40-65, have about overactive bladder (OAB) and what they are prepared to do about its symptoms. Using constructs from the Health Belief Model, this survey aims to explain the fears and preparedness women have towards general health and OAB. This research is conducted by Kelton Global Research, a market research company and supported by a grant from Merck Pharmaceuticals.

26 Oct 2012

Online resource for men diagnosed with low-grade prostate cancer launched

Johns Hopkins Medicine, along with the Prostate Cancer Foundation and Cedars-Sinai Medical Center, have launched the National Proactive Surveillance Network, an online resource for men diagnosed with low-grade prostate cancer that can be slow-growing and non-life-threatening in up to 50 percent of diagnosed cases.

25 Oct 2012

New biomarker measures aggressiveness of primary prostate tumors

Research out of Roswell Park Cancer Institute (RPCI) supports the adoption of a new biomarker to measure the aggressiveness of primary prostate tumors.

24 Oct 2012

Large hospitals not following CAUTI preventive guidelines in their ICUs

Hospital size matters when it comes to intensive care units (ICUs) adopting even the most routine prevention policies for catheter-associated urinary tract infections (CAUTI), according to a new study from researchers at Columbia University School of Nursing, published this month in the American Journal of Infection Control.

24 Oct 2012

AUA introduces new guidelines for treatment of OAB, urodynamics, hematuria and vasectomy

The American Urological Association (AUA) introduces new clinical guidelines for the treatment of Overactive Bladder, Urodynamics, Hematuria, and Vasectomy.

24 Oct 2012

Urology News and Research

Latest Urology News and Research

Taiho Pharmaceutical announces early stage data for eight novel oncology compounds

Monoclonal antibody boosts cholesterol reduction

Endo, Bioniche decide to end second Urocidin Phase III trial on non-muscle-invasive bladder cancer

Men with prostate cancer can benefit from active surveillance

Toilet training method not related to urinary accidents in children

Imatinib mesylate effectively treats children with neurofibromatosis type 1 tumors

Multiple sclerosis disease activity reduced by leukaemia drug, even when first-line treatment has failed

Encouraging results from stereotactic radiosurgery Phase I trial on kidney cancer

Watson acquires Actavis

Prognostic impact of Gleason score modernization undetermined

High vitamin D levels associated with protection against bladder cancer

Sequana Medical announces CE mark approval of alfapump for patients with malignant ascites

Metabolic syndrome increases erectile dysfunction risk

Scientists identify mechanism via Top2b enzyme that drives doxorubicin-induced heart damage

FDA approves Watson’s generic Actos

NAFC conducts online survey to examine women’s perceptions about overactive bladder

Online resource for men diagnosed with low-grade prostate cancer launched

New biomarker measures aggressiveness of primary prostate tumors

Large hospitals not following CAUTI preventive guidelines in their ICUs

AUA introduces new guidelines for treatment of OAB, urodynamics, hematuria and vasectomy

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Urology News and Research

Latest Urology News and Research

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in